Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD

Status: Completed
Location: See all (22) locations...
Study Type: Observational
SUMMARY

Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material derived from the blood and/or bone marrow. The results of these studies will be correlated with subjects' disease symptoms and response to their experimental treatment. The MPD-RC researchers are interested in studying molecules from the blood and bone marrow, the exact molecules changing over time with the investigators choosing only the most promising for investigation. The investigators are attempting to better understand the causes of MPD and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is believed that further basic knowledge about these cancer cells as well as the effects of treatment will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. The MPD-RC is hoping to determine if a number of laboratory tests (biomarkers) will allow for the prediction of response in future patients to the treatment they would receive.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Patients are to be registered to this study if they meet the eligibility criteria for one of the MPD-RC treatment protocols linked to this study.

• Patients diagnosed with the following Myeloproliferative disorders including: polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) who are participating in treatment protocols of the MPD-RC are eligible.

• Patients must have signed an informed consent to participate in a Myeloproliferative Disorders Research Consortium (MPD-RC) treatment study to which this protocol is a companion study. The subject must also have signed a consent to participate in this mandatory companion study.

Locations
United States
Arizona
Mayo Clinic
Scottsdale
California
The Palo Alto Clinic
Palo Alto
Washington, D.c.
Georgetown University
Washington
Georgia
Emory Hospital
Atlanta
Illinois
University of Illinois at Chicago
Chicago
Maryland
University of Maryland
Baltimore
North Carolina
Duke University Medical Center
Durham
Wake Forest University Baptist Medical Center
Winston-salem
New York
Icahn School of Medicine at Mount Sinai
New York
New York Blood Center
New York
Weill Cornell Medical College
New York
Ohio
Ohio State University
Columbus
Pennsylvania
Geisinger Cancer Center
Hazleton
University of Pennsylvania
Philadelphia
Utah
University of Utah
Salt Lake City
Other Locations
Canada
Princess Margaret Cancer Centre
Toronto
Italy
Ospedali Riuniti di Bergamo
Bergamo
University of Florence
Florence
Ospedale San Martino Genova
Genova
San Matteo Hospital
Pavia
Universita Cattolica del Sacro Cuore
Rome
United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London
Time Frame
Start Date: April 2007
Completion Date: July 20, 2018
Participants
Target number of participants: 592
Authors
Ruben Mesa, Harsh Gandhi, Tsiporah Shore, Murat Arcasoy, Elizabeth Hexner, Craig Kessler, Damiano Rondelli, Maria Baer, John Mascarenhas, Rebecca Klisovic, Dmitry Berenzon, Gianni Barosi, David Liebowitz, Vikas Gupta, Giuseppe Leone, Allessandro Vannucchi, Josef Prachal, Rona S Weinberg, Andrea Bacigalupo, Mario Cazzola, Alessandro Rambaldi, Elliot Winton, Claire Harrison
Sponsors
Collaborators: Myeloproliferative Disorders-Research Consortium, National Cancer Institute (NCI)
Leads: Icahn School of Medicine at Mount Sinai

This content was sourced from clinicaltrials.gov

Similar Clinical Trials